Senzime AB (publ) has acquired MD Biomedical AB, a company that has developed and patented products for microdialysis. The acquisition enables Senzime to offer a complete patient monitoring system, focusing on intensive care. The acquisition is financed by newly issued shares in Senzime.
Lindahl's team consisted of Mattias Prage (lead partner), Helena Lindbäck, Sofia Lysén and Marcus Andersson.
